China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its in-house developed recyclable vena cava filter, ZYLOX Octoplus, for the prevention of pulmonary embolism (PE) caused by peripheral deep vein thrombosis (DVT).
Market Outlook and Growth Projections
It is estimated that the number of DVT patients in China will increase from 15 million in 2019 to 33 million in 2030, with a compound annual growth rate of 7.3%. In China, interventional surgery, including inferior vena cava filter (IVCF) placement, has become the first choice for the treatment of lower extremity DVT. The number of IVCF interventions in China is projected to increase from 85,700 in 2019 to 673,700 in 2030, with a compound annual growth rate of 20.6%.
Innovative Features of ZYLOX Octoplus
ZYLOX Octoplus features an innovative structural design, with excellent immediate adherence performance to the vena cava and excellent independent balance ability. The filter release is more accurate, and the long-term thrombus interception is more efficient. Additionally, the product can reduce the risk of pulmonary embolism, prolong the thrombolytic treatment window, and improve the cure rate of deep vein thrombosis.-Fineline Info & Tech
